n-methylaspartate has been researched along with Idiopathic Parkinson Disease in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (50.00) | 18.2507 |
| 2000's | 8 (22.22) | 29.6817 |
| 2010's | 6 (16.67) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Frouni, I; Huot, P | 1 |
| Bassi, MS; Buttari, F; Carta, M; Centonze, D; De Rosa, A; Di Maio, A; Errico, F; Gilio, L; Morelli, M; Nuzzo, T; Sasabe, J; Serra, M; Sulzer, D; Usiello, A | 1 |
| Liu, M; Tuo, J; Xu, Z; Yu, C; Zhang, F; Zhang, J; Zhang, L | 1 |
| Fan, H; Huang, J; Lai, X; Liu, A; Qiao, L; Shen, M; Wu, J; Yan, J | 1 |
| Borsello, T; Cimini, S; Garção, P; Giorgini, F; Hassanjani, M; Lilley, KS; Maddison, DC; Outeiro, TF; Panman, L; Patel, B; Repici, M; Straatman, KR; Szegö, ÉM | 1 |
| Kuo, CC; Lai, WS; Liu, WC; Pan, MK; Pei, JC; Tai, CH | 1 |
| Fantin, M; Morari, M | 1 |
| Anandakkuttan, A; Kannoth, S; Mathai, A; Nambiar, V; Sasikumar, AN | 1 |
| Di Rocco, A; Howard, J; Varanese, S | 1 |
| Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U | 1 |
| Boldyrev, AA; Bychkova, ON; Tuneva, EO | 1 |
| Emmett, SR; Greenfield, SA | 1 |
| Litvinenko, IV | 1 |
| Jankovic, J; Olanow, CW | 1 |
| Kress, GJ; Reynolds, IJ | 1 |
| Gu, Z; Lipton, SA; Ma, Y; Masliah, E; Nakamura, T; Nomura, Y; Shi, ZQ; Uehara, T; Yao, D | 1 |
| Amano, T; Hiji, M; Hirabayashi, T; Kohriyama, T; Matsumoto, M; Nagano, Y; Nakamura, T; Sakai, N; Takahashi, T; Yagi, T; Yamashita, H | 1 |
| Ossowska, K | 1 |
| Klockgether, T; Turski, L | 2 |
| Danysz, W; Quack, G; Rogoz, Z; Skuza, G | 1 |
| Boldry, RC; Chase, TN; Engber, TM | 1 |
| Brunner, LC; Cotman, CW; Joyce, JN; Marshall, JF; Ułas, J; Weihmuller, FB | 1 |
| Meldrum, BS | 1 |
| Blin, O; Fabre, N; Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Chouinard, ML; Gaitan, D; Wood, PL | 1 |
| Amarnath, V; Graham, DG; Montine, TJ; Picklo, MJ; Whetsell, WO | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; Natté, R; van den Munckhof, P; Verhagen Metman, L | 1 |
| Klockgether, T; Löschmann, PA; Spieker, S | 1 |
| Müller, T | 1 |
| Kornhuber, J; Weller, M | 1 |
| Bubser, M; Hauber, W; Schmidt, WJ | 1 |
| Carlsson, A; Carlsson, M; Svensson, A | 1 |
| Carlsson, A; Carlsson, M | 1 |
| Greenamyre, JT; O'Brien, CF | 1 |
11 review(s) available for n-methylaspartate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; N-Methylaspartate; Parkinson Disease | 2022 |
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
Topics: Aged; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Middle Aged; N-Methylaspartate; Neuroinflammatory Diseases; Parkinson Disease; Quality of Life; Receptors, N-Methyl-D-Aspartate | 2023 |
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline | 2010 |
[Dementia and psychotic disorders in parkinsonism: common origin and new perspectives in therapy].
Topics: Dementia; Humans; N-Methylaspartate; Neurotransmitter Agents; Parkinson Disease; Psychotic Disorders; Receptors, N-Methyl-D-Aspartate | 2004 |
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E | 2005 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease Models, Animal; Excitatory Amino Acids; Levodopa; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats | 1994 |
The role of glutamate in epilepsy and other CNS disorders.
Topics: Animals; Central Nervous System Diseases; Epilepsy; Glutamic Acid; Humans; Lamotrigine; Mice; N-Methylaspartate; Parkinson Disease; Piperazines; Pyrimidines; Rats; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Sodium Channels; Triazines | 1994 |
Non-dopaminergic drug treatment of Parkinson's disease.
Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists | 2001 |
Behavioural pharmacology of glutamate in the basal ganglia.
Topics: Animals; Basal Ganglia; Glutamates; Humans; Models, Neurological; Motor Activity; N-Methylaspartate; Parkinson Disease; Receptors, Glutamate; Stereotyped Behavior | 1992 |
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.
Topics: Animals; Anticonvulsants; Aspartic Acid; Basal Ganglia; Biogenic Amines; Dibenzocycloheptenes; Dizocilpine Maleate; Glutamates; Glutamic Acid; Humans; N-Methylaspartate; Parkinson Disease; Schizophrenia | 1990 |
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
Topics: Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; gamma-Aminobutyric Acid; Globus Pallidus; Humans; N-Methylaspartate; Nerve Tissue Proteins; Neural Pathways; Parkinson Disease; Phosphoproteins; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Trihexyphenidyl | 1991 |
2 trial(s) available for n-methylaspartate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
A trial of dextromethorphan in parkinsonian patients with motor response complications.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dextromethorphan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Motor Skills; N-Methylaspartate; Neurologic Examination; Parkinson Disease | 1998 |
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Parkinson Disease; Pilot Projects; Piperidines; Severity of Illness Index | 1999 |
23 other study(ies) available for n-methylaspartate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients.
Topics: Alzheimer Disease; Amino Acids; Amyotrophic Lateral Sclerosis; Homeostasis; Humans; N-Methylaspartate; Parkinson Disease; Putamen; Receptors, N-Methyl-D-Aspartate; Serine | 2023 |
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dopaminergic Neurons; Hippocampus; Inflammation; Mice, Inbred C57BL; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Simvastatin | 2020 |
The Parkinson's Disease-Linked Protein DJ-1 Associates with Cytoplasmic mRNP Granules During Stress and Neurodegeneration.
Topics: Animals; Cytoplasmic Granules; HEK293 Cells; Humans; Mice; N-Methylaspartate; Nerve Degeneration; Neurons; Osmotic Pressure; Oxidative Stress; Parkinson Disease; Protein Binding; Protein Deglycase DJ-1; Rats; Ribonucleoproteins; Stress, Physiological | 2019 |
Deranged NMDAergic cortico-subthalamic transmission underlies parkinsonian motor deficits.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Electrophysiological Phenomena; Excitatory Amino Acid Antagonists; Locomotion; Male; Mice; Motor Cortex; Motor Skills; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Receptors, Glutamate; Subthalamic Nucleus | 2014 |
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Globus Pallidus; Male; Microdialysis; N-Methylaspartate; Neostriatum; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2015 |
Autoimmune atypical parkinsonism - A group of treatable parkinsonism.
Topics: Aged; Autoimmune Diseases; Azathioprine; Female; Glutamate Decarboxylase; Humans; Immunosuppressive Agents; Immunotherapy; Intracellular Signaling Peptides and Proteins; Longitudinal Studies; Male; Middle Aged; Mycophenolic Acid; N-Methylaspartate; Parkinson Disease; Proteins; Retrospective Studies | 2016 |
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Incidence; Levodopa; Male; Memantine; N-Methylaspartate; Parkinson Disease | 2010 |
Effect of NMDA on production of reactive oxygen species by human lymphocytes.
Topics: Humans; Luminescent Measurements; Lymphocytes; N-Methylaspartate; Parkinson Disease; Reactive Oxygen Species; Tetradecanoylphorbol Acetate | 2003 |
A peptide derived from the C-terminal region of acetylcholinesterase modulates extracellular concentrations of acetylcholinesterase in the rat substantia nigra.
Topics: Acetylcholine; Acetylcholinesterase; Amino Acid Sequence; Amyloid beta-Protein Precursor; Animals; Calcium Signaling; Disease Models, Animal; Drug Interactions; Extracellular Fluid; Male; Molecular Sequence Data; N-Methylaspartate; Neurons; Parkinson Disease; Peptide Fragments; Protein Structure, Tertiary; Rats; Rats, Wistar; Substantia Nigra | 2004 |
Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn; Brain; Cell Death; Cell Nucleus; Cerebral Cortex; Corpus Striatum; Dopamine; Drug Synergism; Glutamic Acid; N-Methylaspartate; Nerve Degeneration; Neurons; Neurotoxins; Organ Culture Techniques; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
Topics: Alzheimer Disease; Animals; Binding Sites; Cell Line; Cysteine; Endoplasmic Reticulum; Humans; Molecular Chaperones; N-Methylaspartate; Neurodegenerative Diseases; Nitric Oxide; Parkinson Disease; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Disulfide-Isomerases; Protein Folding; Receptors, G-Protein-Coupled; Sulfhydryl Compounds; Ubiquitin | 2006 |
Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Blotting, Western; Cell Death; Cell Differentiation; Cells, Cultured; Disease Models, Animal; DNA-Binding Proteins; Dose-Response Relationship, Drug; Embryo, Mammalian; Fluorescent Antibody Technique; Humans; Membrane Potentials; Mice; Mice, Inbred C57BL; Mutant Proteins; N-Methylaspartate; Nerve Tissue Proteins; Neurons; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidative Stress; Parkinson Disease; Patch-Clamp Techniques; Stem Cells; Transcription Factors | 2006 |
Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Basal Ganglia; Cycloleucine; Electromyography; Glutamates; Glutamic Acid; Kainic Acid; Male; Muscles; N-Methylaspartate; Parkinson Disease; Rats; Receptors, Glutamate | 1993 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 1994 |
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain Diseases; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Male; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Autoradiography; Binding Sites; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Glutamic Acid; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; N-Methylaspartate; Nerve Tissue Proteins; Parkinson Disease; Receptors, Amino Acid; Receptors, AMPA; Receptors, Glutamate | 1994 |
N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
Topics: Aged; Dextromethorphan; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; N-Methylaspartate; Neurologic Examination; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 1994 |
Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in human temporal cortex: comparison of normal, Parkinson, and Alzheimer tissues.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Gas Chromatography-Mass Spectrometry; Humans; Middle Aged; N-Methylaspartate; Parkinson Disease; Rats; Receptors, Glycine; Receptors, Neurotransmitter; Reference Values; Serine; Temporal Lobe | 1993 |
[NMDA antagonists--current aspects of the pathogenesis and therapy of Parkinson disease].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; N-Methylaspartate; Parkinson Disease | 1997 |
Neurotoxicity of endogenous cysteinylcatechols.
Topics: Animals; Brain Chemistry; Carcinoma, Embryonal; Catechols; Cells, Cultured; Culture Media; Cysteine; Dopamine; Electron Transport; Excitatory Amino Acid Antagonists; Hippocampus; Magnetic Resonance Spectroscopy; N-Methylaspartate; NAD(P)H Dehydrogenase (Quinone); Neuroglia; Oxidation-Reduction; Parkinson Disease; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Tumor Cells, Cultured | 1997 |
N-methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome.
Topics: Dopamine; Humans; N-Methylaspartate; Neuroleptic Malignant Syndrome; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 1992 |
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice.
Topics: Adrenergic alpha-Agonists; Animals; Atropine; Biperiden; Clonidine; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Ketamine; Male; Methyldopa; Mice; Mice, Neurologic Mutants; Motor Activity; N-Methylaspartate; Parasympatholytics; Parkinson Disease; Piperazines | 1991 |
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
Topics: Animals; Dizocilpine Maleate; Drug Synergism; Electromyography; Levodopa; Male; Methyltyrosines; Motor Activity; Muscle Rigidity; N-Methylaspartate; Parkinson Disease; Piperazines; Rats; Rats, Inbred Strains; Reserpine | 1990 |